|
The role of hydroxychloroquine in COVID-19: Where do we stand?
Ranjit Mohan Anjana1, Nadiminty Ganapathi Sastry2, Muthu Ramuu2, Prasanna Kumar Gupta2, Jaggi Shalini2, Brijendra Kumar Srivastava2, Chaithanya Murthy Kocherlakota2, Tata Sameer Nandan2, Gangadhara Praveen2, Jyotish Nair2, Routray Philips2, Viswanathan Mohan1, Ranjit Unnikrishnan1
1 Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, Chennai, Tamil Nadu, India; Department of Diabetology, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India
2 Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, Chennai, Tamil Nadu, India
Correspondence Address:
Dr. Ranjit Mohan Anjana
Department of Diabetology, Madras Diabetes Research Foundation and Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, 4, Conran Smith Road, Gopalapuram, Chennai 600086, Tamil Nadu.
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JOD.JOD_33_20
|
|
Hydroxychloroquine (HCQ) is a drug, which has long been used in the treatment of malaria, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren’s syndrome. Recently with the COVID-19 pandemic hitting the world, there have been studies suggesting that hydroxychloroquine may be useful both in the prevention and the treatment of COVID-19, although the evidence so far has been conflicting. This article reviews the available evidence for the use of hydroxychloroquine in COVID-19 and also mentions some of the ongoing trials in this field. |
